Stock Update: Actavis plc (NYSE:ACT) – Actavis Confirms Generic Butrans® Patent Challenge

[PR Newswire] – DUBLIN, Sept. 25, 2014 /PRNewswire/ — Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) . . . → Read More: Stock Update: Actavis plc (NYSE:ACT) – Actavis Confirms Generic Butrans® Patent Challenge Similar Articles: Company Update (NYSE:ACT): Actavis Announces FDA Acceptance of the NDA Filing for Ceftazidime-Avibactam, a Qualified Infectious Disease Product Company Update (NYSE:ACT): Actavis to Present at Morgan Stanley Global Healthcare Conference 2014 Company Update (NYSE:ACT): Actavis Announces Positive Topline Results From The Phase III Program Of Ceftazidime-Avibactam In Patients With Complicated Intra-Abdominal Infections(cIAI)